Next Generation Bioprocessing is considered to be any technology, expendable, or system which significantly changes the existing monoclonal antibody manufacturing template to deliver higher productivity, increased manufacturing flexibility, increased speed, and reduced risk.
Meet our expert to get insights and perspectives on the on-going paradigm shift and evolution towards Next Generation Bioprocessing occurring in today’s and tomorrow’s biopharmaceutical landscape.
|Track 2:||Integrated Processing and Novel Development Strategies|
|(Predictive Models, PAT, Continuous Processing, Single-use Systems)|
|10:45 - 11:15||Intensification of Monoclonal Antibody Platform processing: A case-study on “Inline flocculation for harvest clarification”|
|Paul Kaschutnig, EMEA Process Development Scientist, Merck|
Flocculation are recently being accepted in the mAb platform process to deal with high cell densities coming out of the bioreactor. It brings increased throughput, reduces turbidity and enhances impurity removal. We will show how even more efficient clarification process can be designed by applying in-line flocculation.
This approach addresses certain facility constraints in a GMP manufacturing.
The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the US and Canada.
Cité Internationale – Centre de Congrès, Lyon
50 Quai Charles de Gaulle
69463 Lyon, France